Allergy Therapeutics (LON:AGY) Stock Price Down 7.8% – What’s Next?

Allergy Therapeutics plc (LON:AGY) was down 7.8% during mid-day trading on Monday . The company traded as low as GBX 9.60 and last traded at GBX 10. Approximately 241,736 shares traded hands during trading, a decline of 13% from the average daily volume of 278,121 shares. The stock had previously closed at GBX 10.85.

Allergy Therapeutics Price Performance

The stock has a market capitalization of £633.25 million, a PE ratio of -10.31, a PEG ratio of -30.70 and a beta of 0.91. The company has a current ratio of 1.13, a quick ratio of 1.48 and a debt-to-equity ratio of 629.58. The company’s 50 day simple moving average is GBX 10.73 and its 200 day simple moving average is GBX 10.46.

Allergy Therapeutics (LON:AGY) last released its earnings results on Tuesday, March 31st. The company reported GBX (0.38) EPS for the quarter. The firm had revenue of GBX 3,628 million during the quarter. Allergy Therapeutics had a positive return on equity of 409.00% and a negative net margin of 85.46%. On average, equities analysts anticipate that Allergy Therapeutics plc will post -2.56 earnings per share for the current year.

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.